SEC Tracker
Get the app

Oric Pharmaceuticals ORIC

Oric Pharmaceuticals (Oric) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational progress. The filing highlights Oric's continued advancement of its oncology drug pipeline, a critical focus area for the company as it seeks to deliver innovative treatments to cancer patients. This quarterly update is crucial for investors to assess Oric's short-term performance and long-term growth potential.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Oric Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Geron GERN public float $861M, Jun 30, 2025
  2. Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
  3. Wave Life Sciences WVE public float $851M, Jun 30, 2025
  4. CorMedix CRMD public float $910M, Jun 30, 2025
  5. Niagen Bioscience NAGE public float $814M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.